Pasithea Therapeutics (KTTA) Stock: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.49
0.08 (18.98%)
â˛
5d:
+19.15%
30d:
-5.12%
90d:
+1.58%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KTTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KTTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.49, which is considered fair relative to its 30-day fair value range of $0.43 to $0.51.
Technical Outlook: Technically, KTTA is in a downtrend. The price is approaching resistance at $0.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 19.0% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.00 (+515.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KTTA is in a downtrend. The price is approaching resistance at $0.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 19.0% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.00 (+515.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.43 -
$0.51
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+19.0%)
- BULLISH: Trading 515.0% below Wall St target ($3.00)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.43 -
$0.51
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.38
Resistance Level
$0.50
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.06
Wall Street Target
$3.00
(+515.0%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: October 22, 2026 8:54 AM ET
Data refreshes hourly during market hours. Next update: 9:54 AM
Data refreshes hourly during market hours. Next update: 9:54 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 47 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$144 | 71 BUY |
